July 27, 2021

Evaluation of the efficacy and safety of an anti-tau antibody in older adults with early Alzheimer’s disease is in progress

AbbVie, an American publicly traded biopharmaceutical company founded in 2013, is conducting this trial since October 2016 through 2022, wherein participants will receive an injection containing either one of three doses of ABBV-8E12 or a placebo.

Researchers will study the effects of ABBV-8E12, an anti-tau antibody, on abnormal tau accumulation, a hallmark of Alzheimer’s disease. Researchers will also compare changes in participants’ dementia symptoms, cognitive function, and activities of daily living and will also track any safety issues.

Check out the inclusion and exclusion criteria on this link: https://www.nia.nih.gov/alzheimers/clinical-trials/abbv-8e12-early-alzheimers-disease

Leave a Reply

Your email address will not be published. Required fields are marked *

Hey there!
Would you like to be notified when we publish new content?

You have successfully subscribed

There was an error while trying to send your request. Please try again.

Hopeful Trials & News will use the information you provide on this form to be in touch with you and to provide updates and marketing.